Investor Presentaiton

Generic APIs Q1 impact reversing 680 632 Revenue Growth API Sales mix 714 [* Cr] 8% 12% 9% 18% 19% 23% 33% 29% 22% 33% ■ Onco API 629 Y-o-Y 8% ■ Other API 597 Q-o-Q▲ 5% 68% ■ ARV API 59% 59% 59% 49% 2Q FY23 3Q FY23 4Q FY23 1Q FY24 2Q FY24 Comments 21 2Q 3Q 4Q 1Q 2Q FY23 FY23 FY23 FY24 FY24 ■ API business improved sequentially driven by resumption of shipments in non-ARV segment; however overall declined YoY ■ H1 revenues stable as steady ARV API (-1%) and strong delivery in Oncology compensated for decline in Other API (-24%) Oncology sharply rebounded on favorable demand dynamics, reporting revenue increase of 129% YoY and 117% QoQ. Oncology API additional capacity being created in Unit 3 ■ ARV business retained volume led steady momentum, though Q2 moderated a bit attributing to cyclicality in ordering; declined 8% both YoY and sequentially ■ Other APIs slightly recovered; +2% growth QoQ. CMO order book visibility remain healthy Laurus Q2 & H1 FY 2024 Investor Presentation | October 20, 2023 LAURUS Labs Knowledge. Innovation. Excellence

View entire presentation